Pfizer (PFE) stock prices updated...
 

Pfizer stock price

Pfizer latest news:


  • 09/21/2017 15:00:23

    Versartis shares halted

    Shares of Versartis Inc. were halted late Thursday after the biopharmaceutical company said its drug somavaratan failed to meet its primary endpoint in a phase 3 trial. The drug, a form of human growth hormone that seeks to treat growth-hormone deficiency, failed to demonstrate superiority to Genotropin, an offering from Pfizer Inc. , in a study focusing on pediatric growth-hormone deficiency. "We are very surprised and disappointed to learn the outcome," Chief Executive Jay Shepard said in Thursday's announcement, adding that the company planned to provide a corporate update later this year. Versartis shares have gained 27% in the past three months, more than 10 times the gains for the S&P 500 Index in the same period, and nearly 45% so far this year. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/20/2017 13:35:29

    Pfizer accuses Johnson & Johnson of 'anticompetitive practices' in lawsuit

    Pfizer filed a lawsuit against fellow pharmaceutical giant Johnson & Johnson over "anticompetitive practices" with the drug Remicade.        

  • 09/20/2017 13:24:42

    Pfizer files suit against J&J over Remicade contracts

    (Reuters) - Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson , saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

  • 09/14/2017 14:01:13

    United Technologies, Pfizer Lead DJIA Higher on Thursday


  • 09/14/2017 11:35:30

    Why Pfizer Is Pushing the Dow to All-Time Highs


  • 09/14/2017 09:29:24

    Pfizer, Astellas prostate cancer drug promising in late-stage trial

    * Xtandi meets main goal in late-stage trial. * Analyst says expanded use to double market size. * Pfizer's shares up 1.8 pct. By Divya Grover. Pfizer Inc (PFE) and Japan's Astellas Pharma Inc (ALPMF) said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages.

  • 09/14/2017 04:11:57

    Pfizer, Astellas prostate cancer drug clears late-stage trial

    Pfizer Inc(PFE) and Astellas Pharma Inc (ALPMF) said on Thursday their drug to treat a type of prostate cancer met the main goal in a late-stage trial. The drug, Xtandi, in combination with an anti-hormone therapy showed statistically significant improvement in metastasis-free survival rate in men with non-metastatic castration-resistant prostate cancer when compared with the standalone anti-hormone therapy.

  • 09/07/2017 12:11:32

    FDA warns of serious manufacturing violations in letter to EpiPen manufacturing facility

    The Food and Drug Administration described "significant violations of current good manufacturing practice" in a warning letter to a Pfizer unit that manufactures Mylan's EpiPen allergic reaction treatment. The unit, Meridian Medical Technologies Inc., "failed to thoroughly investigate multiple serious component and product failures... including failures associated with patient deaths and severe illness," the warning letter said, referring to an FDA inspection of a Missouri manufacturing facility between February and March of this year. "You also failed to expand the scope of your investigations into these serious and life-threatening failures or take appropriate corrective actions, until FDA's inspection." The regulator asked the company to review its manufacturing investigations and provide its plan for addressing safety risks, all within 15 days. If the company doesn't promptly fix the violations, there may be legal action, and the FDA may not approve applications listing the manufacturing facility, the FDA said. Mylan shares declined nearly 1% in moderate Thursday afternoon trade, while Pfizer shares rose a scant 0.3% in heavy trade, compared with a 0.1% decline in the S&P 500 Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/01/2017 09:58:15

    FDA approves Pfizer's leukemia drug

    (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved Pfizer Inc's drug, Mylotarg, for certain patients with acute myeloid leukemia (AML).

  • 09/01/2017 09:53:58

    UPDATE 1-FDA approves Pfizer's leukemia drug

    Sept 1 (Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved Pfizer Inc's drug, Mylotarg, for certain patients with acute myeloid leukemia (AML).

  • 09/01/2017 09:39:47

    BRIEF-Pfizer receives FDA approval for MYLOTARG (gemtuzumab ozogamicin)

    * Pfizer receives FDA approval for MYLOTARG (gemtuzumab ozogamicin) Source text for Eikon: Further company coverage:

  • 08/31/2017 14:01:42

    DuPont, Pfizer Carry DJIA Higher Thursday


  • 08/26/2017 10:03:00

    Is the System Rigged Against Biosimilars?

    Pfizer and Amgen are encountering problems getting traction for their biosimilars. Is the system rigged against them?

  • 08/25/2017 09:50:58

    BRIEF-Pfizer and Sangamo updates on early stage trial on its blood disorder therapy

    Pfizer Inc(PFE): * Sangamo and Pfizer announce first patient receives treatment in Phase 1/2 clinical trial evaluating SB-525 investigational gene therapy for Hemophilia A Source text for Eikon: Further company coverage:

  • 08/17/2017 14:22:05

    BRIEF-Pfizer receives FDA approval for BESPONSA (inotuzumab ozogamicin)

    * Pfizer receives U.S. FDA approval for BESPONSA (inotuzumab ozogamicin) Source text for Eikon: Further company coverage:

  • 08/17/2017 11:40:31

    BRIEF-U.S. FDA approves Pfizer's leukemia drug Besponsa ‍​

    U.S. Food and Drug Administration: * U.S. FDA approved Besponsa for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia ‍​. * FDA granted the approval of Besponsa to Pfizer Inc.‍​. * Prescribing information for Besponsa includes a boxed warning that severe liver damage occurred in some patients who took Besponsa‍​. * Boxed warning also i...

  • 08/14/2017 16:16:16

    BRIEF-Soros Fund Management dissolves share stake in Tesla, Pfizer, ConocoPhillips

    Soros Fund Management: * Soros Fund Management dissolves share stake in Tesla Inc (TSLA) - SEC filing. * Soros Fund Management dissolves share stake in Pfizer Inc (PFE). * Soros Fund Management dissolves share stake in ConocoPhillips.

  • 08/14/2017 15:26:44

    Tepper's Appaloosa dumps Snap Inc., stake, loads up on tech, health care

    David Tepper's hedge fund Appaloosa Management unloaded its position in Snapchat-parent Snap Inc., and disclosed increases in the tech and health-care sectors at the end of the second quarter. As of June 30, Tepper's fund showed that his fund dumped 100,000 shares of of Snap Inc. , which has lost more than a third of its value since it debuted as a public entity in early March. Tepper had been one of a number of prominent investors who had vocally expressed support of the social-messaging company. On Monday, Snap's shares were among the most active, gaining about 6.5% to start the week. Elsewhere, Appaloosa showed new positions in the PowerShares QQQ Trust Series 1 , which mimics the technology laden Nasdaq-100 , purchasing 1.8 million shares of the so-called QQQs, valued at $249 million, representing about 3.7% of his overall portfolio, according to data from research provider Whalewisdom.com. The fund also more than doubled its Apple Inc. position to 625,000 shares worth about $90 million and those of Altaba Inc. , which he boosted to 5.1 million shares valued at $280 million. Appaloosa showed a fresh stake in Alibaba Group Holding Limited , scooping up 3.6 million shares worth $520 million. Tepper's investment vehicle added a new position in exchange-traded IBB , a prominent ETF tracking the biotech sector, and SPDR S&P Biotech ETF , which closely mimics the S&P 500's health-care sector. Tepper's firm bought 235,000 shares of IBB worth about $73 million and 330,000 shares of XBI valued at $34 million, as of the end of June. In other sales, Tepper & Co. unloaded all of its position in Teva Pharmaceutical Industries , Energy Transfer Partners L.P. and Pfizer Inc. among others. Related: Active-managers have a new favorite toolMarket Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/14/2017 15:14:19

    Tepper's Appaloosa dumps Snap Inc. stake, loads up on tech, health care

    David Tepper's hedge fund Appaloosa Management unloaded its position in Snapchat-parent Snap Inc., and disclosed increases in the tech and health-care sectors at the end of the second quarter. As of June 30, Tepper's fund showed that his fund dumped 100,000 shares of of Snap Inc. , which has lost more than a third of its value since it debuted as a public entity in early March. Tepper had been one of a number of prominent investors who had vocally expressed support of the social-messaging company. On Monday, Snap's shares were among the most active, gaining about 6.5% to start the week. Elsewhere, Appaloosa showed new positions in the PowerShares QQQ Trust Series 1 , which mimics the technology laden Nasdaq-100 , purchasing 1.8 million shares of the so-called QQQs, valued at $249 million, representing about 3.7% of his overall portfolio, according to data from research provider Whalewisdom.com. The fund also more than doubled its Apple Inc. position to 625,000 shares worth about $90 million and those of Altaba Inc. , which he boosted to 5.1 million shares valued at $280 million. Appaloosa showed a fresh stake in Alibaba Group Holding Limited , scooping up 3.6 million shares worth $520 million. Tepper's investment vehicle added a new position in exchange-traded IBB , a prominent ETF tracking the biotech sector, and SPDR S&P Biotech ETF , which closely mimics the S&P 500's health-care sector. Tepper's firm bought 235,000 shares of IBB worth about $73 million and 330,000 shares of XBI valued at $34 million, as of the end of June. In other sales, Tepper & Co. unloaded all of its position in Teva Pharmaceutical Industries , Energy Transfer Partners L.P. and Pfizer Inc. among others.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/14/2017 14:41:40

    BRIEF-Appaloosa dissolves share stake in Snap Inc, Pfizer Inc

    Appaloosa Lp: * Appaloosa Lp dissolves class a share stake in Snap Inc (SNAP) - SEC Filing. * Appaloosa Lp ups share stake in Apple Inc (AAPL) to 625,000 from 300,000.

  • 08/09/2017 09:47:54

    Mexico watchdog finds big pharma faces no competition on some drugs

    Pharmaceutical companies including GlaxoSmithKline, Pfizer and Sanofi-Aventis face no competition for certain drugs in Mexico from generics that are readily available elsewhere, a senior Mexican anti-trust official said on Wednesday.

  • 08/01/2017 11:36:25

    Key drug sales push Pfizer profit up 50 percent

    Rising sales of several key drugs, lower one-time charges and reduced manufacturing costs helped drugmaker Pfizer raise its profit 50 percent in the second quarter

  • 08/01/2017 11:35:11

    Key drug sales push Pfizer profit up 50 percent

    Pfizer is reporting second-quarter profit of $3.07 billion.

  • 07/25/2017 15:36:13

    Adviser charged with insider trading on Pfizer-King deal pleads guilty

    NEW YORK, July 25 (Reuters) - A Long Island, New York, investment adviser accused of engaging in insider trading after being tipped off about Pfizer Inc's $3.6 billion acquisition of King Pharmaceuticals Inc pleaded guilty on Tuesday, federal prosecutors said.

  • 07/04/2017 11:51:50

    Pfizer receives token payment to exit Brazil venture, sources say

    SAO PAULO (Reuters) - Pfizer Inc has agreed to exit Laboratório Teuto Brasileiro SA for a token amount after failing to find a buyer for the 40 percent stake it held in the Brazilian generic drugmaking joint venture, two people with knowledge of the matter said on Tuesday.

  • More trends:

    Pharmerica CorporationPMC | PHH CorpPHH | Philip Morris International IncPM | Philippine Long Distance Telephone CompanyPHI | Phillips 66PSX | Phillips 66 Partners LPPSXP | Phoenix CompaniesPFX | Phoenix CompaniesPNX | Phoenix New Media LimitedFENG | Physicians Realty TrustDOC |